Amgen Inc/ US0311621009 /
2024-03-18 9:00:00 PM | Chg. +2.0300 | Volume | Bid1:56:11 PM | Ask1:56:11 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
270.9000USD | +0.76% | 3.61 mill. Turnover: 697.19 mill. |
270.0000Bid Size: 100 | 271.8700Ask Size: 100 | 145.18 bill.USD | 3.19% | 21.57 |
GlobeNewswire
03-18
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digita...
GlobeNewswire
03-18
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire
03-18
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-14
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GlobeNewswire
03-12
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire
03-07
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busine...
GlobeNewswire
03-07
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC C...
GlobeNewswire
03-06
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business...
GlobeNewswire
03-05
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...
GlobeNewswire
03-04
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
GlobeNewswire
02-29
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
GlobeNewswire
02-28
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...